Oncotelic Therapeutics (OTCQB: OTLC) has launched an AI-powered manufacturing services platform designed to address a critical bottleneck in biotechnology: access to full Good Manufacturing Practice (GMP) infrastructure. The platform integrates Oncotelic’s proprietary PDAOAI(TM) architecture with digital manufacturing technologies and intelligent robotics developed in collaboration with TechForce Robotics, the company’s strategic robotics and automation partner. The initiative aims to apply artificial intelligence not only to drug discovery but also to manufacturing workflows, helping therapies transition more efficiently from development to commercialization.
Already deployed at Oncotelic’s GMP-certified SAPU manufacturing facility to support its own clinical pipeline, the platform adds a second layer to the company’s business model. While Oncotelic remains a clinical-stage biotech, the AI-GMP platform could extend its role into enabling infrastructure for other drug developers. If adopted commercially, it creates a services-based revenue opportunity while strengthening Oncotelic’s internal development engine. Combined with TechForce Robotics’ automation capabilities, the launch reflects a broader industry shift toward intelligent manufacturing systems that reduce manual workload and tighten compliance discipline.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, particularly for high-unmet-need cancers and rare pediatric indications. The company’s CEO, Dr. Vuong Trieu, has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, Oncotelic also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership, which is advancing its own pipeline of drug candidates that complement Oncotelic’s strategic position.
For more information, visit https://ibn.fm/OTLC.
